company background image
ESPR

Esperion Therapeutics NasdaqGM:ESPR Stock Report

Last Price

US$6.36

Market Cap

US$400.7m

7D

1.1%

1Y

-70.2%

Updated

30 Jun, 2022

Data

Company Financials +
ESPR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ESPR Stock Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.

Esperion Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Esperion Therapeutics
Historical stock prices
Current Share PriceUS$6.36
52 Week HighUS$21.68
52 Week LowUS$3.28
Beta0.42
1 Month Change11.58%
3 Month Change28.23%
1 Year Change-70.24%
3 Year Change-86.53%
5 Year Change-86.52%
Change since IPO-56.14%

Recent News & Updates

May 07

Esperion Therapeutics: 2021 Labors Paying Off In 2022

Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue. The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year. Esperion had a 32% year-over-year cost savings of the company operating expenses compared to the first quarter of 2021. The company believes they are "financed through the readout of the CLEAR Outcomes trial and for the foreseeable future beyond that". I believe investors should be applauding Esperion's recent success and ought to be enthusiastic about the company’s long-term potential.

Shareholder Returns

ESPRUS PharmaceuticalsUS Market
7D1.1%0.9%-0.6%
1Y-70.2%10.5%-21.7%

Return vs Industry: ESPR underperformed the US Pharmaceuticals industry which returned 11.3% over the past year.

Return vs Market: ESPR underperformed the US Market which returned -20.8% over the past year.

Price Volatility

Is ESPR's price volatile compared to industry and market?
ESPR volatility
ESPR Average Weekly Movement12.7%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: ESPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ESPR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008218Sheldon Koenighttps://www.esperion.com

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.

Esperion Therapeutics Fundamentals Summary

How do Esperion Therapeutics's earnings and revenue compare to its market cap?
ESPR fundamental statistics
Market CapUS$400.72m
Earnings (TTM)-US$234.90m
Revenue (TTM)US$89.31m

4.5x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ESPR income statement (TTM)
RevenueUS$89.31m
Cost of RevenueUS$121.90m
Gross Profit-US$32.59m
Other ExpensesUS$202.31m
Earnings-US$234.90m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.73
Gross Margin-36.50%
Net Profit Margin-263.03%
Debt/Equity Ratio-211.0%

How did ESPR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ESPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESPR?

Other financial metrics that can be useful for relative valuation.

ESPR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.9x
Enterprise Value/EBITDA-3.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ESPR's PS Ratio compare to its peers?

ESPR PS Ratio vs Peers
The above table shows the PS ratio for ESPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.5x
TARS Tarsus Pharmaceuticals
15.9x60.7%US$384.4m
AMYT Amryt Pharma
1.9x21.4%US$448.3m
ANIP ANI Pharmaceuticals
2.1x11.7%US$481.5m
AVIR Atea Pharmaceuticals
2.1x42.3%US$591.1m
ESPR Esperion Therapeutics
4.5x45.2%US$400.7m

Price-To-Sales vs Peers: ESPR is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (5.5x).


Price to Earnings Ratio vs Industry

How does ESPR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: ESPR is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Pharmaceuticals industry average (3.9x)


Price to Sales Ratio vs Fair Ratio

What is ESPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio6.3x

Price-To-Sales vs Fair Ratio: ESPR is good value based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (6.3x).


Share Price vs Fair Value

What is the Fair Price of ESPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ESPR ($6.36) is trading below our estimate of fair value ($74.44)

Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ESPR is expected to become profitable in the next 3 years.

Revenue vs Market: ESPR's revenue (45.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ESPR's revenue (45.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Esperion Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-13.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ESPR is currently unprofitable.

Growing Profit Margin: ESPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).


Return on Equity

High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Esperion Therapeutics's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ESPR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Sheldon Koenig (55 yo)

1.08yrs

Tenure

US$7,776,226

Compensation

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...


CEO Compensation Analysis

Compensation vs Market: Sheldon's total compensation ($USD7.78M) is above average for companies of similar size in the US market ($USD2.86M).

Compensation vs Earnings: Sheldon's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ESPR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: ESPR's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ESPR insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 123.5%.


Top Shareholders

Company Information

Esperion Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: ESPR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$400.722m
  • Shares outstanding: 63.01m
  • Website: https://www.esperion.com

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.